3 Stocks That May Be Trading Below Their Estimated Value

In This Article:

As global markets navigate mixed signals, with major U.S. stock indexes closing a strong year despite recent volatility and economic indicators like the Chicago PMI showing contraction, investors are increasingly focusing on identifying opportunities that may be undervalued amidst these fluctuations. In such an environment, a good stock is often characterized by its potential for growth relative to its current price, making it crucial for investors to assess whether certain stocks might be trading below their estimated value.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Livero (TSE:9245)

¥1565.00

¥3120.65

49.9%

Camden National (NasdaqGS:CAC)

US$42.01

US$83.84

49.9%

Brickability Group (AIM:BRCK)

£0.626

£1.25

49.8%

Decisive Dividend (TSXV:DE)

CA$6.00

CA$11.94

49.8%

Zhaojin Mining Industry (SEHK:1818)

HK$11.72

HK$23.44

50%

Brunel International (ENXTAM:BRNL)

€9.84

€19.64

49.9%

Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme (ATSE:MOTO)

€2.73

€5.44

49.8%

Constellium (NYSE:CSTM)

US$10.47

US$20.81

49.7%

Neosperience (BIT:NSP)

€0.572

€1.14

49.8%

Vogo (ENXTPA:ALVGO)

€2.92

€5.81

49.8%

Click here to see the full list of 888 stocks from our Undervalued Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

SK bioscienceLtd

Overview: SK bioscience Co., Ltd. focuses on the research, development, production, and distribution of vaccines and biopharmaceuticals both in Korea and internationally, with a market cap of approximately ₩3.99 trillion.

Operations: The company's revenue segment primarily comprises pharmaceuticals, generating approximately ₩201.30 billion.

Estimated Discount To Fair Value: 49.3%

SK bioscience is trading significantly below its estimated fair value, with a valuation 49.3% lower than anticipated. Despite past shareholder dilution, the company shows promising growth prospects, with earnings expected to increase by 57.59% annually and revenue projected to grow faster than the Korean market at 17.8% per year. Recent advancements in mRNA vaccine technology and international approvals for its influenza vaccine further bolster its potential for future profitability and market expansion.

KOSE:A302440 Discounted Cash Flow as at Jan 2025
KOSE:A302440 Discounted Cash Flow as at Jan 2025

Zhaojin Mining Industry

Overview: Zhaojin Mining Industry Company Limited is an investment holding company involved in the exploration, mining, processing, smelting, and sale of gold and silver products in the People’s Republic of China with a market cap of approximately HK$39.67 billion.